

(Bio-pharmaceutics & Pharmacokinetics Question Bank SEM-VIII)

Q.1is defined as rate and extent of drug absorption.

- a. Bioavailability
- b. Bioequivalence
- c. drug disposition
- d. absorption

Q.2. The movement of drug from one compartment to other compartment is referred as...

- a. Bioavailability
- b. drug distribution
- c. drug disposition
- d. absorption

Q.3. Passive transport process involve all except.....

- a. Passive diffusion
- b. Pore transport
- c. ion-pair transport
- d. Antiport

Q.4. Facillated diffusion is also known as.....

- a. Active diffusion
- b. mediated diffusion
- c. ion-pair transport
- d. Symport

Q.5. is active transport process

- a. Persorption
- b. Pinocytosis
- c. Phagocytosis
- d. ion-pair transport

Q.6. BCS Class III have....

- a. Low solubility & Low permeability
- b. High solubility & low permeability
- c. Low Solubility & High permeability
- d. High solubility & high permeability

Q.7. Equation for zero order half life is.....

- a. $t_{1/2} = 0.5 A_0/k_0$
- b. $t_{1/2} = 2A_0/k_0$
- c. $t_{1/2} = 1.5 A_0/k_0$
- d. $t_{1/2} = 0.693 A_0/k_0$

Q.8. Equation for first order half life is.....

- a. $t_{1/2} = 0.5 A_0/k_0$
- b. $t_{1/2} = 2A_0/k_0$
- c. $t_{1/2} = 1.5 A_0/k_0$
- d. $t_{1/2} = 0.693/k$

Q.9. In cell uptake studies use of peristaltic pump is required for.....

- a. Single pass perfusion
- b. Everted Sac Technique
- c. Doluisio method
- d. Everted Ring Technique

Q.10. Blood brain barrier consist of specialized cells except.....

- a. Astrocytes
- b. Endoblasts
- c. Pericytes
- d. Endothelial cells

Q.11. Formula for volume of distribution is.....

- a. $V_d = C/X$
- b. $V_d = X/C$
- c. $V_d = K_e/X$
- d. $V_d = K_e/C$

Q.12. Resident time for large intestine is.....

- a. 2 hrs
- b. 6-12 hrs
- c. 4 hrs
- d. 3 hrs

Q.13. Intestinal transit time for Duodenum is.....

- a. 0.5 to 1 hrs
- b. 3 to 6 hrs
- c. 2 hrs
- d. 5 minute

Q.14. Majority of drug that binds to extravascular tissues, the order of binding is

- a. Liver>Kidney>Lung>Muscles
- b. Lung>Liver>Kidney>Muscles
- c. Liver> Lung >Kidney >Muscles
- d. Liver>Kidney> Muscles>Lung

Q.15. Which of this is not phase II reaction

- a. Acetylation
- b. Methylation
- c. Hydrolysis of esters
- d. Conjugation of glucuronic acid

Q.16. Clearance is defined as the ration of.....

- a. Elimination rate/Plasma drug Concentration
- b. Plasma drug Concentration/ Elimination rate
- c. V_d/AUC
- d. AUC/V_d

Q.17. The beginning of pharmacological response is called as....

- a. Onset time
- b. Duration of action
- c. Onset of action
- d. Intensity of action

Q.18. Which of this is model independent approach of pharmacokinetics....

- a. Mammillary model
- b. Perfusion model
- c. Distributed parameter model
- d. Noncompartmental analysis

Q.19. Absorption rate constant can be calculated by

- a. Method of residuals
- b. Sigma minus method
- c. Model independent method
- d. Noncompartmental analysis

Q.20. First order pharmacokinetic model equation is

- a. $\text{Log}C = \text{Log}C_0 - K_{Et}/2.303$
- b. $\text{Log}C = \text{Log}C_0 - K_E/2.303$
- c. $\text{Log}X = \text{Log}C_0 - K_{Et}/2.303$
- d. $\text{Log}C_0 = \text{Log}C - 2.303/K_{Et}$

Q.21. Bioavailability is generally in the order of.....

- a. Oral > Parenteral > Rectal > Topical
- b. Parenteral > Oral > Topical > Rectal
- c. Oral > Parenteral > Topical > Rectal
- d. Parenteral > Oral > Rectal > Topical \

Q.22. Flow through cell belongs to which type of USP apparatus

- a. USP type 1
- b. USP type 2
- c. USP type 4
- d. USP type 3

Q.23. ...is used for molecular inclusion complexation for solubility enhancement of drugs

- a. Sodium Lauryl sulphate
- b. Cyclodextrine
- c. CMC
- d. HPMC

Q.24. IV bolus dose of 200 mg given by IV. Following one compartment kinetics described by equation $C = e^{-0.91t}$. Calculate CIT, Vd.

- a. 0.0173 ml/min, 1.44 ml
- b. 0.0273 ml/min, 2.5 ml
- c. 0.0785 ml/min, 3.22ml
- d. 0.0673 ml/min, 4.44 ml

Q.25. IV bolus dose of 25mg given by IV. Following one compartment kinetics having half life is 36 hrs and volume of distribution is 27000 lt. Calculate CIT, C_0 .

- a. 8640 ml/min, 0.00092 mg/lit
- b. 5220 ml/min, 0.92 mg/lit
- c. 8520 ml/min, 0.92 mg/lit
- d. 5220 ml/min, 0.092 mg/lit

Q.26 The enteral route of administration involves all except

- a. Buccal
- b. Gastrointestinal
- c. Rectal
- d. Subcutaneous

Q.27. The USP apparatus type 5 is...

- a. Paddle over disk
- b. Cylinder
- c. Reciprocating disc
- d. Flow-through cell

Q.28. Model independent approach belongs to pharmacokinetic model

- a. Physiological
- b. Compartment
- c. Distributed
- d. Non-compartment

Q.29. In method of dissolution comparison the values f_1 and f_2 refers to...&....

- a. Dissolution factor, Difference Factor
- b. Difference Factor, Dissolution factor
- c. Difference Factor, Similarity factor
- d. Similarity factor, Difference Factor

Q.30. BCS class IV drugs have

- a. Low solubility & High permeability
- b. Low solubility & Low permeability
- c. High solubility & High permeability
- d. High solubility & Low permeability

Q.31. Movement of drug molecules through the skin under the influence of ultrasound is known as.....

- a. Phonophoresis
- b. Iontophoresis
- c. Phagocytosis
- d. Endocytosis

Q.32. Unionised drug have.....&.....values

- a. Low K_b & High $K_{o/w}$
- b. High K_a & High $K_{o/w}$
- c. High K_a & High $K_{o/w}$
- d. Low K_a & High $K_{o/w}$

Q.33. For the disruption of Blood brain barrier following agents are used except...

- a. Dihydropyridine redox system
- b. Sodium Chloride
- c. Mannitol
- d. Dimethyl sulphoxide

Q.34. Thiopental is.....&..... acting drug

- a. Hydrophobic, Peripherally
- b. Lipophilic, Peripherally
- c. Hydrophilic, Centrally
- d. Lipophilic, Centrally

Q.35. Marker used to measure the volume of Erythrocytes in physiological fluid compartment is

- a. Cr-15
- b. Evance Blue
- c. I-131
- d. Albumin

Q.36. Binding site IV for human serum albumin is also called as.....

- a. Warfarin binding site
- b. Tamoxifen binding site
- c. Diazepam binding site
- d. Digitoxin binding site

Q.37. Gamma globulins specifically binds to.....

- a. Transcortin
- b. Transferrin
- c. Antigens
- d. Carotenoids

Q.38. Mean residence time can be determined by.....

- a. Compartment model
- b. Non-compartment model
- c. Physiological model
- d. Trapezoidal Rule

Q.39. Route of administration considered having highest bioavailability is

- a. Intramuscular
- b. Transdermal
- c. Intra-arterial
- d. Oral

Q.40. Equation for Clearance Cl_T are stated, all correct except.....

- a. $Cl_T = KE \cdot V_d$
- b. $Cl_T = (dt/dx)/V_d$
- c. $Cl_T = 0.693 V_d / t_{1/2}$
- d. $Cl_T = FX_0 / AUC$

Q.41. The ability of liver to excrete the drug in the bile is called as

- a. Biliary clearance
- b. Renal Clearance
- c. Volume of distribution
- d. Total Clearance

Q.42. Therapeutic Index and Therapeutic window are ration of...&... respectively

- a. $MEC/MSC \cdot 100$ & $MSC/MEC \cdot 100$
- b. MSC/MEC & MEC/MSC
- c. $MSC/MEC \cdot 100$ & $MEC/MSC \cdot 100$
- d. MEC/MSC & MSC/MEC

Q.43. Which of the following belongs to Secondary transport

- a. Organic anion transport
- b. Facillated diffusion
- c. Antiport
- d. Carrier mediated transport

Q.44. Steady state concentration is the ration of

- a. Infusion rate/ Clearance
- b. Clearance rate/ Blood flow
- c. V_d / Clearance
- d. Cl_T/V_d

Q.45. Michaelis menten equation is

- a. $dC/dt = V_{max} \cdot C / K_m + C$
- b. $-dC/dt = V_{max} \cdot C / K_m + C$
- c. $dT/dC = V_{max} / K_m + C$
- d. $-dC/dt = V_{max} / K_m + C$

Q.46. Bioavailability of drug is determined by formula...

- a. $F = \frac{[AUC]_{\text{oral}} \cdot \text{Dose}_{\text{iv}}}{[AUC]_{\text{iv}} \cdot \text{Dose}_{\text{oral}}}$
- b. $F = \frac{[AUC]_{\text{iv}} \cdot \text{Dose}_{\text{oral}}}{[AUC]_{\text{oral}} \cdot \text{Dose}_{\text{iv}}}$
- c. $F = \frac{[AUC]_{\text{iv}} \cdot \text{Dose}_{\text{iv}}}{[AUC]_{\text{oral}} \cdot \text{Dose}_{\text{oral}}}$
- d. $F = \frac{[AUC]_{\text{oral}} \cdot \text{Dose}_{\text{oral}}}{[AUC]_{\text{iv}} \cdot \text{Dose}_{\text{iv}}}$

Q.47. Mean residence time is the ratio of.....

- a. AUC/V_d
- b. $AUC/AUMC$
- c. AUC/K_E
- d. $AUMC/AUC$

Q.48. For Weak Bases formula for pH is

- a. $pH = pK_a + \log \frac{[\text{Ionised drug}]}{[\text{Unionised drug}]}$
- b. $pH = pK_a + \log \frac{[\text{Unionised drug}]}{[\text{Ionised drug}]}$
- c. $pH = pK_a + \frac{[\text{Ionised drug}]}{[\text{Unionised drug}]}$
- d. $pH = pK_a + \frac{[\text{Unionised drug}]}{[\text{Ionised drug}]}$

Q.49. IV bolus dose of 325 mg given by IV. Following one compartment kinetics described by equation have $V_d = 960$ lit & half-life 14 hrs. Calculate Cl_T , C_0 .

- a. 620 ml/min, 0.101 mg hr/lit
- b. 420 ml/min, 0.868 mg hr/lit
- c. 340 ml/min, 0.412 mg hr/lit
- d. 792 ml/min, 0.3385 mg hr/lit

Q.50. IV bolus dose of 125 mg given by IV. Following one compartment kinetics having half life is 12 hrs and volume of distribution is 8000 lt. Calculate Cl_T , C_0 .

- a. 7700 ml/min, 0.015625 mg/lit
- b. 6255 ml/min, 0.1269 mg/lit
- c. 3685 ml/min, 0.258 mg/lit
- d. 6156 ml/min, 0.2536 mg/lit